The harsh portfolio!

Hi,

Thanks for sharing these, I think you are looking at the wrong places. Please read their rights issue document to see their main products (summary below).

Here are my product specific notes:

• Majority of our Pharmaceutical products belongs to Anti-psychotic and Anti-parasitic Drug family accounting for 60-70% of our turnover while few intermediates go into anti diabetic, anti-viral and anti-arrhytmic. The Company is also actively engaged in catering to the Specialty fine chemicals and polymer industry using it’s core chemical expertise whose contribution to the turnover ranges from 10-20%.
• Pharmaceutical intermediates used in the Anti-Psychotic therapeutic areas are responsible for 29%, 21%, and 10% of our total revenue from operations for the FY19, FY20, and FY21. We supply our products to more than one hundred and thirteen (113) customers directly and indirectly through our network of distributors in the overseas markets which exports its products to more than seventeen (17) countries. Further, our top five (5) customers constitute approximately 47% of our total revenue from operations for FY21
• Since our inception in 2004 we have developed and manufactured approximately fifty (50) pharmaceutical intermediates for APIs such as Amitryptiline, Nortryptline, Haloperidol etc.

In terms of capacity, these are their existing capacities and utilization trends. Their current expansion will increase manufacturing capacity by 2000 MTPA

Detailed notes at link below.

https://twitter.com/theHarshFolio/status/1649009766931505152